A new drug called dostarlimab saw astonishing results in a 12-person rectal cancer trial: Every one of the dozen patients went into remission. All the patients were still in remission in a six-month follow-up of the trial as well. Additionally, none of the patients had received chemoradiotherapy or undergone any preventative surgery, and no cases… Continue reading Remission seen in every rectal cancer patient in small study of drug
Remission seen in every rectal cancer patient in small study of drug
